CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES

人们需要新的避孕方法，这些方法可以防止意外怀孕并降低静脉血栓栓塞（VTE）的风险，特别是对于肥胖女性。CCTN的使命是制定方案并进行临床试验，以帮助肥胖妇女提供有效和安全的避孕措施。美国国立卫生研究院（NIH）、尤妮斯·肯尼迪·施莱佛国家儿童健康和人类发展研究所（NICHD）、是进行基础和临床研究的主要联邦机构，以开发新的避孕药具，并评估现有的避孕和生殖方法。健康1968年，卫生、教育和福利部长在国家排雷中心内设立了人口研究中心，其重要目标是通过合同和赠款开发新的避孕药具。在预防和控制方案内，避孕和生殖健康分支处长期以来一直支持几个临床前避孕测试设施， 用于合成化学品和合成肽制剂的设施。为了进一步扩大其避孕开发能力，CRHB于1996年建立了NICHD避孕临床试验网络。目前的CCTN已经进行了女性和男性避孕方法的I期、II期和III期临床试验。随着CCTN的重新竞争，临床研究中心将对各种新的或现有的肥胖女性避孕方法进行I期、II期、III期和IV期临床试验。

There is a demand for new methods of contraception than can provide protection against unintended pregnancies as well as reduce risk of venous thromboembolism (VTE), particularly for obese women. The mission of the CCTN is to develop protocols and conduct clinical trials that assist in providing effective and safe contraception in obese women.The National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is the lead Federal agency for the conduct of basic and clinical research to develop new contraceptives and to evaluate existing methods of contraception and reproductive health. The Center for Population Research (CPR), within NICHD, was established in 1968 by the Secretary of Health Education and Welfare, with the important goal of developing new contraceptives through the use of contracts and grants. Within CPR, the Contraception and Reproductive Health Branch (CRHB) has long supported several preclinical contraceptive testing facilities as well as facilities for synthetic chemical and synthetic peptide formulation. To further expand their contraceptive development capabilities, in 1996 CRHB established the NICHD Contraceptive Clinical Trials Network (CCTN). The current CCTN has conducted Phase I, II, and III clinical trials of both female and male contraceptive methods. With the recompetition of the CCTN, clinical sites will perform Phase I, II, III, and Phase IV clinical trials of a wide variety of new or existing obese female contraceptive methods.